Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

G. V. Long, K. T. Flaherty, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, V. Chiarion-Sileni, C. Lebbe, M. Mandala, M. Millward, A. Arance, I. Bondarenko, J. B. A. G. Haanen, J. Hansson, J. Utikal, V. FerraresiP. Mohr, V. Probachai, D. Schadendorf, P. Nathan, C. Robert, A. Ribas, M. A. Davies, S. R. Lane, J. J. Legos, B. Mookerjee, J. J. Grob

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences